Vinblastine
Velban (vinblastine) is a small molecule pharmaceutical. Vinblastine was first approved as Velban on 1982-01-01. It is used to treat breast neoplasms, choriocarcinoma, head and neck neoplasms, histiocytosis, and hodgkin disease amongst others in the USA. The pharmaceutical is active against tubulin beta chain.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
neoplasms | D009369 |
respiratory tract diseases | D012140 |
urogenital diseases | D000091642 |
hemic and lymphatic diseases | D006425 |
skin and connective tissue diseases | D017437 |
endocrine system diseases | D004700 |
immune system diseases | D007154 |
signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vinblastine sulfate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VELBAN | Eli Lilly | N-012665 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
vinblastine sulfate | ANDA | 2019-12-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
choriocarcinoma | — | D002822 | C58 |
head and neck neoplasms | — | D006258 | — |
histiocytosis | HP_0100727 | D015614 | — |
hodgkin disease | — | D006689 | C81 |
kaposi sarcoma | — | D012514 | C46 |
kidney neoplasms | EFO_0003865 | D007680 | C64 |
lung neoplasms | — | D008175 | C34.90 |
mycosis fungoides | — | D009182 | C84.0 |
testicular neoplasms | — | D013736 | C62 |
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J9360 | Injection, vinblastine sulfate, 1 mg |
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | 7 | 6 | — | 15 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | 1 | — | 2 |
Morbidity | D009017 | — | — | — | 1 | — | 1 | ||
Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | 1 | — | 1 |
Separation anxiety | D001010 | EFO_1001916 | — | — | — | 1 | — | 1 | |
Depression | D003863 | F33.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
Social phobia | D000072861 | EFO_1001917 | F40.1 | — | — | — | — | 1 | 1 |
Hot flashes | D019584 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | VINBLASTINE |
INN | vinblastine |
Description | Vincaleukoblastine is a vinca alkaloid, an indole alkaloid fundamental parent, a methyl ester, an acetate ester, a tertiary alcohol, a tertiary amino compound, an organic heterotetracyclic compound and an organic heteropentacyclic compound. It has a role as a microtubule-destabilising agent, an antineoplastic agent, a plant metabolite and an immunosuppressive agent. |
Classification | Small molecule |
Drug class | antihistaminics (histamine-H1 receptor antagonists); vinca alkaloids |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1 |
Identifiers
PDB | — |
CAS-ID | 865-21-4 |
RxCUI | 11198 |
ChEMBL ID | CHEMBL159 |
ChEBI ID | — |
PubChem CID | 241903 |
DrugBank | DB00570 |
UNII ID | 5V9KLZ54CY (ChemIDplus, GSRS) |
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 22,027 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,650 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more